TY -的T1阐明早期cy的进展stic fibrosis lung disease JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01916-2017 VL - 50 IS - 5 SP - 1701916 AU - Ramsey, Kathryn AU - Ratjen, Felix AU - Latzin, Philipp Y1 - 2017/11/01 UR - //www.qdcxjkg.com/content/50/5/1701916.abstract N2 - Widespread implementation of newborn screening has allowed early diagnosis and disease detection in infants with cystic fibrosis (CF). Early surveillance has shown that pulmonary infection and inflammation occur early in life, and are associated with the development of structural disease as well as lung function decline in childhood [1, 2]. With the advent of disease-modifying therapies for CF, and evidence of their efficacy in adults and adolescents [3], there is a need for sensitive outcome measures to monitor efficacy and safety of these therapies in infancy.Findings that infants with CF followed up regularly have mild, transient lung function deficits are encouraging http://ow.ly/SOKN30fRn3I ER -